ATE470478T1 - An ovarialkrebs beteiligtes protein - Google Patents

An ovarialkrebs beteiligtes protein

Info

Publication number
ATE470478T1
ATE470478T1 AT04769011T AT04769011T ATE470478T1 AT E470478 T1 ATE470478 T1 AT E470478T1 AT 04769011 T AT04769011 T AT 04769011T AT 04769011 T AT04769011 T AT 04769011T AT E470478 T1 ATE470478 T1 AT E470478T1
Authority
AT
Austria
Prior art keywords
cdcp1
protein involved
ovarial cancer
modulate
expression
Prior art date
Application number
AT04769011T
Other languages
English (en)
Inventor
Nicola Anne Burgess
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29595617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE470478(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE470478T1 publication Critical patent/ATE470478T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
AT04769011T 2003-10-22 2004-10-22 An ovarialkrebs beteiligtes protein ATE470478T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0324656A GB0324656D0 (en) 2003-10-22 2003-10-22 A protein involved in ovarian cancer
PCT/GB2004/004502 WO2005042102A1 (en) 2003-10-22 2004-10-22 A protein involved in ovarian cancer

Publications (1)

Publication Number Publication Date
ATE470478T1 true ATE470478T1 (de) 2010-06-15

Family

ID=29595617

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04769011T ATE470478T1 (de) 2003-10-22 2004-10-22 An ovarialkrebs beteiligtes protein

Country Status (11)

Country Link
US (3) US20070009543A1 (de)
EP (1) EP1677875B1 (de)
JP (1) JP4764344B2 (de)
AT (1) ATE470478T1 (de)
AU (1) AU2004285339B2 (de)
CA (1) CA2541846A1 (de)
DE (1) DE602004027647D1 (de)
ES (1) ES2347249T3 (de)
GB (1) GB0324656D0 (de)
PL (1) PL1677875T3 (de)
WO (1) WO2005042102A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
AU2007210124A1 (en) * 2006-01-26 2007-08-09 The Trustees Of The University Of Pennsylvania Tumor vasculature markers and methods of use thereof
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
US8664358B2 (en) 2007-06-29 2014-03-04 Vermillion, Inc. Predictive markers for ovarian cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
EP2971259B8 (de) 2013-03-13 2018-11-21 NantEnergy, Inc. Synergistische additive für elektrochemische zellen mit elektrolytbrennstoff
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
EP3554544A4 (de) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. Anti-cub-haltige protein 1-(cdcp1)-antikörper, antikörper-wirkstoff-konjugate und verfahren zur verwendung davon
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
EP4055058A4 (de) * 2019-11-06 2023-12-06 Commonwealth Scientific and Industrial Research Organisation Bindung von proteinen an das domäne enthaltende protein (cdcp1)
JP7623705B2 (ja) 2019-12-27 2025-01-29 株式会社カイオム・バイオサイエンス 抗ｃｄｃｐ１抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100869A4 (de) 1998-07-30 2005-04-27 Human Genome Sciences Inc 98 menschliche sekretierte proteine
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
EP1301533A1 (de) 2000-07-07 2003-04-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
US20020142003A1 (en) * 2000-07-07 2002-10-03 Norbert Schweifer Tumor-associated antigen (B345)
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
CN100422328C (zh) * 2003-02-19 2008-10-01 诺瓦提斯公司 在人转移性肿瘤细胞中表达的糖蛋白抗原sima135

Also Published As

Publication number Publication date
EP1677875B1 (de) 2010-06-09
ES2347249T3 (es) 2010-10-27
EP1677875A1 (de) 2006-07-12
US20110059088A1 (en) 2011-03-10
JP4764344B2 (ja) 2011-08-31
US20070009543A1 (en) 2007-01-11
US8263071B2 (en) 2012-09-11
PL1677875T3 (pl) 2010-11-30
DE602004027647D1 (de) 2010-07-22
US9120860B2 (en) 2015-09-01
GB0324656D0 (en) 2003-11-26
US20130230524A1 (en) 2013-09-05
CA2541846A1 (en) 2005-05-12
WO2005042102A1 (en) 2005-05-12
JP2007513873A (ja) 2007-05-31
AU2004285339A1 (en) 2005-05-12
AU2004285339B2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
EA202091710A1 (ru) Антитела против cd73 и способы их применения
MX2022002682A (es) Anticuerpos anti-cd73.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
NO20083053L (no) Humane monoklonale antistoffer mot O8E
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
SG163554A1 (en) Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CY1126007T1 (el) Προαγωγεις αποπτωσης
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DK1951759T3 (da) Anti-EGFR-antistoffer
MX358705B (es) Agentes de union de esclerostina.
ATE251942T1 (de) Stapelbare statische mischelemente
EA200600038A1 (ru) Антитела, специфические в отношении склеростина, и способы увеличения минерализации кости
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EP1844077A4 (de) Dr5-antikörper und deren verwendung
UA108193C2 (uk) Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
JOP20230311A1 (ar) أجسام مضادة لـ sirp-ألفا
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
ATE470478T1 (de) An ovarialkrebs beteiligtes protein
EA202092487A1 (ru) Ферменты кинурениназы человека и их применение

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1677875

Country of ref document: EP